MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Stock Price
MLTXStock
$14.99−72.65%52W
Market Cap$1.28B
P/E—
PEG Ratio—
Div yield—
Beta1.05
MLTX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-29.57%
Price vs S&P 500 (4W)-15.39%
VGM Score26.22
MLTX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.90 | -$0.84 | +6.20%(+$0.06) | |
| Q1 2026 | -$0.92 | -$0.98 | -6.38%(-$0.06) | |
| Q4 2025 | -$0.94 | -$0.92 | +2.60%(+$0.02) | |
| Q3 2025 | -$0.92 | -$1.10 | -20.17%(-$0.18) | |
| Q2 2025 | -$0.76 | -$0.87 | -14.28%(-$0.11) |
MLTX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.00
3.95
3.95
3.95
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MLTXMoonLake Immunotherapeutics Class A Ordinary Shares | — | — | D | $14.99 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About MoonLake Immunotherapeutics Class A Ordinary Shares
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing SLK, a tri-specific Nanobody that inhibits IL-17A and IL-17F to treat inflammatory skin and joint diseases. Clinical data suggest SLK has potential for disease modification in dermatology and rheumatology indications where IL-17A and IL-17F drive pathophysiology.